Clinigen Continues Strategic Shift
Clinigen divests global rights to four cancer support therapies in support of move to solidify services.
In its continued efforts to increase the company’s focus on its pharmaceutical services market, Clinigen has divested four cancer supportive care products from its brands portfolio to CNX Therapeutics, a specialty pharmaceutical company. Those products, Cardioxane®, Savene®, Totect® and Ethyol®, address side effects patients may experience when treated with other cancer therapies. The financial terms for the divestment were not disclosed. Earlier this year, Clinigen sold Proleukin® to Iovance Biotherapeutics.
It also divested its European-based contract development business Lamda Laboratories SA, to Adragos Pharma GmbH. And late last year, Clinigen acquired Drug Safety Navigator, a specialist pharmacovigilance service provider based in the US.
The Clinigen services portfolio includes clinical trials sourcing, clinical supplies management, managed access and pharmacovigilance.
Jerome Charton, CEO of Clinigen, commented in a press release, “This divestment marks another milestone in Clinigen’s continued strategic evolution towards providing high-value services to the pharmaceutical and biotech sectors. These medicines have been integral to Clinigen, but as we refocus our efforts, it is crucial to align our offerings with our core strategy…”
Reference: “Clinigen divests global rights to four cancer support therapies to CNX Therapeutics,” 8/10/23. Clinigen press release.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
